Study details
Enrolling now
MDMA-Assisted Massed Exposure Therapy for PTSD
Emory University
NCT IDNCT07288151ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
200
Study length
about 4 years
Ages
21–70
Locations
1 site in GA
About this study
Researchers are testing if MDMA combined with Massed Prolonged Exposure (PE) therapy helps people with PTSD. The trial will compare this treatment to PE alone, and a placebo. The goal is to see if the combination of MDMA and PE leads to better results than just PE or a placebo in reducing PTSD symptoms.
Based on ClinicalTrials.gov records.
What participants do
- 1.Participate in Massed Prolonged Exposure (PE)
- 2.Take 3,4-Methylenedioxymethamphetamine (MDMA)
- 3.Take Placebo
PhasePhase 2
Routeoral
Primary goalChanges in PTSD symptoms measured by CAPS-5-R
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low14%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
oral
Endpoints
Primary: Changes in PTSD symptoms measured by CAPS-5-R
Secondary: Changes in PTSD symptoms measured by PCL-5
Body systems
Psychiatry / Mental Health